Followers | 829 |
Posts | 119653 |
Boards Moderated | 16 |
Alias Born | 09/05/2002 |
Saturday, November 19, 2022 12:22:19 PM
https://www.nytimes.com/2022/11/18/health/fda-type-1-diabetes-delay.html
There’s a dilemma vis-à-vis the right time to start therapy. If started too early—i.e. when the patient has detectable autoimmune antibodies but does not yet have damage to the pancreas—Tzield may not work. OTOH, if therapy is started too late—when damage to the pancreas has already occurred—the clinical benefit is reduced to some degree.
A further problem is that screening for autoimmune antibodies capable of causing T1D is rarely done unless a patient has close relatives already diagnosed with T1D.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
FEATURED Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • May 16, 2024 8:13 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM
HealthLynked Corp Announces First Quarter 2024 Results: Achieves 8% Revenue Growth Over Last Quarter • HLYK • May 16, 2024 8:00 AM
Integrated Ventures Files Q3/2024 With Mining Revenues Of $1,983,250 And Positive Earnings Of $0.05 Cents Per Share • INTV • May 15, 2024 10:30 AM
Swifty Global Announces Impressive Financial Results for Q1 2024 • DRCR • May 15, 2024 10:25 AM